We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+5.44%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.59B
AUM Growth
+$1.23B
(+28%)
Cap. Flow
-$770M
Cap. Flow
% of AUM
-13.79%
Top 10 Holdings %
Top 10 Hldgs %
47.55%
Holding
148
New
37
Increased
36
Reduced
28
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$87.6M |
| 2 |
Burlington
BURL
|
+$81.6M |
| 3 |
Travere Therapeutics
TVTX
|
+$66.9M |
| 4 |
Haemonetics
HAE
|
+$44.2M |
| 5 |
Williams-Sonoma
WSM
|
+$43.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TJX Companies
TJX
|
+$74.6M |
| 2 |
Lantheus
LNTH
|
+$57.7M |
| 3 |
Advance Auto Parts
AAP
|
+$50.2M |
| 4 |
Nike
NKE
|
+$42.9M |
| 5 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$40.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.79% |
| 2 | Consumer Discretionary | 10.03% |
| 3 | Consumer Staples | 7.94% |
| 4 | Communication Services | 2.1% |
| 5 | Industrials | 1.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Alphatec Holdings
ATEC
$1.46B
| $15.3M | 0.27% |
1,000,000
+364,000
| +57% | +$5.61M |
|
|
HBI
77
DELISTED
Hanesbrands
HBI
| $14.9M | 0.27% |
+800,000
| New | +$15.8M |
|
78
SI-BONE Inc
SIBN
$788M
| $14.3M | 0.26% |
456,000
+92,000
| +25% | +$2.98M |
|
79
BioNTech
BNTX
$22.9B
| $14.3M | 0.26% |
64,000
-212,000
| -77% | -$40M |
|
80
Crocs
CROX
$6.14B
| $13.7M | 0.24% |
+117,300
| New | +$11.5M |
|
81
Advantage Solutions
ADV
$522M
| $12.9M | 0.23% |
48,000
+12,000
| +33% | +$3.7M |
|
82
Kiora Pharmaceuticals
KPRX
$11.3M
| $12.2M | 0.22% |
9,296
| – | – |
|
83
McCormick & Company Non-Voting
MKC
$13.7B
| $12M | 0.22% |
+136,000
| New | +$12.1M |
|
|
FREE
84
DELISTED
Whole Earth Brands, Inc. Class A Common Stock
FREE
| $11.9M | 0.21% |
820,000
-380,000
| -32% | -$5.07M |
|
85
Bio-Rad Laboratories Class A
BIO
$8.71B
| $11.6M | 0.21% |
18,000
-20,000
| -53% | -$12.2M |
|
|
TWTR
86
DELISTED
Twitter, Inc.
TWTR
| $10.3M | 0.18% |
+150,000
| New | +$9.2M |
|
87
Deckers Outdoor
DECK
$13.2B
| $9.98M | 0.18% |
+156,000
| New | +$8.8M |
|
|
SIEN
88
DELISTED
Sientra, Inc.
SIEN
| $9.55M | 0.17% |
120,000
+40,800
| +52% | +$2.9M |
|
89
TripAdvisor
TRIP
$1.65B
| $9.03M | 0.16% |
224,000
+64,000
| +40% | +$2.89M |
|
90
Assembly Biosciences
ASMB
$498M
| $8.63M | 0.15% |
185,333
-1,000
| -0.5% | -$49.5K |
|
91
Acco Brands
ACCO
$389M
| $7.21M | 0.13% |
+836,000
| New | +$7.43M |
|
92
AYTU BioPharma
AYTU
$23.9M
| $6.72M | 0.12% |
67,119
| – | – |
|
93
Nomad Foods
NOMD
$1.66B
| $5.65M | 0.1% |
+200,000
| New | +$5.89M |
|
|
TBIO
94
DELISTED
Telesis Bio, Inc. Common Stock
TBIO
| $4.4M | 0.08% |
+11,111
| New | +$3.93M |
|
95
TELA Bio
TELA
$32.7M
| $4.25M | 0.08% |
264,000
+14,000
| +6% | +$192K |
|
96
Tenax Therapeutics
TENX
$363M
| $4.2M | 0.08% |
1,262
| – | – |
|
|
HIND
97
Vyome Holdings
HIND
$14.9M
| $4.08M | 0.07% |
3
+2
| +200% | +$4.75M |
|
|
AMYT
98
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
| $4.08M | 0.07% |
336,000
+136,000
| +68% | +$1.69M |
|
|
RVPH
99
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
| $3.47M | 0.06% |
+35,735
| New | +$3.6M |
|
|
BCTX
100
Briacell Therapeutics
BCTX
$29.9M
| $3.04M | 0.05% |
+3,802
| New | +$2.37M |
|
Similar funds
CRC
RMDI
F
DCP
EW
O
PA
DSC
Armistice Capital's Q2 2021 Portfolio in Review
As of Q2 2021, Armistice Capital held 148 positions worth $5.59B, up 28% from $4.36B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Armistice Capital withdrew a net $770M in Q2 2021, closing 32 positions and reducing 28 holdings. Its most notable exit was TJX Companies, an estimated $74.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
Against the trend, Armistice Capital opened a new position in Iovance Biotherapeutics worth $87.7M.
- Armistice Capital's largest Q2 2021 buy was Iovance Biotherapeutics: 3,372,000 shares worth $87.7M.
- Armistice Capital added most to Travere Therapeutics in Q2 2021, an estimated $66.9M increase.
- Armistice Capital's biggest Q2 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $40.6M.
- Armistice Capital fully exited TJX Companies in Q2 2021, selling an estimated $74.6M.
- Armistice Capital's ten largest holdings make up 48% of its $5.59B portfolio in Q2 2021.
- Armistice Capital opened 37 new positions and closed 32 in Q2 2021.
- Armistice Capital's portfolio value rose 28% quarter-over-quarter to $5.59B.
Based on Armistice Capital's 13F filing for Q2 2021, filed 16 Aug 2021.